Search research articles
Contact Us
Filters
Showing results (231-240 of 261) with videos related to
Page
of 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Cancer Immunology Research
|
January 23, 2024
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy
Jiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Scientific Reports
|
March 10, 2017
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
Yunching Chen, Ya-Chi Liu, Yun-Chieh Sung, et al.
Science Translational Medicine
|
March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 2, 2021
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
William W Ho, Igor L Gomes-Santos, Shuichi Aoki, et al.
Endoscopic Ultrasound
|
June 29, 2019
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol
Adrian Sãftoiu, Manoop S Bhutani, Takao Itoi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab
Ryan J Park, Milan Parikh, Leon Pappas, et al.
Ebiomedicine
|
July 19, 2016
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma
Kern Rei Chng, Sock Hoai Chan, Amanda Hui Qi Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
Christopher G Willett, Yves Boucher, Dan G Duda, et al.
Nature Medicine
|
January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 261) with videos related to
Sort By:
Page
of 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Cancer Immunology Research
|
January 23, 2024
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy
Jiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Scientific Reports
|
March 10, 2017
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
Yunching Chen, Ya-Chi Liu, Yun-Chieh Sung, et al.
Science Translational Medicine
|
March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 2, 2021
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
William W Ho, Igor L Gomes-Santos, Shuichi Aoki, et al.
Endoscopic Ultrasound
|
June 29, 2019
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol
Adrian Sãftoiu, Manoop S Bhutani, Takao Itoi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab
Ryan J Park, Milan Parikh, Leon Pappas, et al.
Ebiomedicine
|
July 19, 2016
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma
Kern Rei Chng, Sock Hoai Chan, Amanda Hui Qi Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
Christopher G Willett, Yves Boucher, Dan G Duda, et al.
Nature Medicine
|
January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
Page
of 27